An observational study in Crohn's Disease, sponsored by Alimentiv Inc.. Active, not recruiting at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Alimentiv Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Crohn Disease with a site in Canada — 50 open to participants now, 79 under way, 26 of them phase 3. Crohn Disease · Canada.
Among the 286 studies in Crohn Disease with a site in Canada, this one is the 17th largest by planned enrollment of the 45 observational ones that give a count, is one of 24 that started in 2024, is one of 45 observational ones, reaches primary completion later than 20 of the 78 other live ones, and was the 246th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →50 of the 286 studies in Crohn Disease with a site in Canada are open now. Recruiting first, the newest first:
AbbVie · Sites in Canada, United States, Israel and 2 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Canada, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Belgium and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Canada, United States, Belgium and 7 more countries
Ages 18–80
University of British Columbia · Sites in Canada
Ages 9–17
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 76 · Phase 3 97 · Phase 4 21
First in 2001; this study’s year is marked. 24 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 145 across the 238 interventional studies, 225 across the 45 observational. Of the 186 that completed or were terminated, 98 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 286 have an industry lead sponsor. The 10 most frequent:
Alimentiv Inc. is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Alimentiv Inc. has 7 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
28 of the studies in Crohn Disease with a site in Canada that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
Add all 28 to your calendar (.ics) → With an account.
Among the 286 studies in Crohn Disease with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.
Vedolizumab (VDZ), a monoclonal antibody that selectively targets intestinal T-cell trafficking, is an effective and safe treatment for moderately to severely active Crohn's disease (CD). Recent evidence from open-label, blinded endpoint studies such as VERSIFY and LOVE-CD provide further support for the efficacy of VDZ in achieving clinical, endoscopic, histologic and radiologic disease improvement in CD. Despite these data, VDZ is generally perceived to have a slower onset of action than other biologics, including tumor necrosis factor (TNF) antagonists and the interleukin (IL)-12/23 antagonist, ustekinumab (UST). The IL-23 antagonist risankizumab (RISA) has been more recently approved for treatment of CD and post-hoc analyses of SEQUENCE trial data showed RISA to be superior to UST for inducing clinical remission at Week 24, and thus, RISA may also be considered to have a quicker onset of action than VDZ. This perception largely emanates from the results of the VDZ pivotal for CD (GEMINI 2) where efficacy was assessed at Week 6 after only 2 doses in a largely refractory population. However, in clinical practice VDZ induction consists of 3 doses of VDZ 300 mg administered intravenously at weeks 0, 2 and 6 instead of the 2 doses used in the pivotal trials. In recent clinical trials, induction endpoints for therapeutics in CD are now typically measured at least after Week 12. Accordingly, it is uncertain whether the generally held perception of a relatively slow onset of action for VDZ is accurate. Moreover, it should also be noted that the perception of a slow onset of action has also been conflated to infer that VDZ is a relatively less effective induction therapy in CD than TNF antagonists or UST. Further data to evaluate these issues are needed.
Rapidity of symptom resolution, which is commonly used as a surrogate for speed of onset, is a priority for patients and clinicians. It is therefore important to better understand the kinetics of symptom improvement captured using patient-reported outcomes (PROs) in patients initiating VDZ for treatment of CD.
This study will be conducted in US and Canadian participants with CD prescribed VDZ or IL-23 antagonists for the first time. Approximately 300 participants with CD who are initiating first-time treatment with VDZ or UIL-23 antagonists will be enrolled in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has a baseline PROMIS Pain Interference-SF score ≥ 15 (corresponding T-score ≥ 55) (PROMIS Pain Interference-SF 8a [V1.1]).
a. Score is calculated by adding score (1 to 5) for each of the 8 subcomponents.
Exclusion Criteria:
Participant has an active infection at baseline requiring intravenous systemic antibiotics.
Note: The treating physician must have completed all appropriate baseline screening tests as per the product label.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group one will include participants who will be starting Vedolizumab as part of routine care. Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider.
Drug: Vedolizumab (VDZ)
Group two will include participants who will be starting an IL-23 antagonist as part of routine care. Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider.
Drug: Ustekinumab (UST) · Drug: Risankizumab (RISA) · Drug: Guselkumab (GUS) · Drug: Mirikizumab (MIR)
Participants will receive VDZ as part of routine care.
Also known as: Entyvio
Participants will receive UST as part of routine care.
Also known as: Stelara
Participants will receive RISA as part of routine care.
Also known as: Skyrizi
Participants will receive GUS as part of routine care.
Also known as: Tremfya
Participants will receive MIR as part of routine care.
Also known as: Omvoh
To assess time of onset of biologic therapy in pain interference
Time to meaningful clinical improvement in pain interference, defined as a ≥ 2-point decrease in the PROMIS Pain Interference-SF T-score
Time frame: Baseline to Week 14
To assess time of onset of biologic therapy in multiple QOL and functioning domains
Time to meaningful clinical improvement for each individual PROMIS domain, defined as a ≥ 2-point change in the direction of improvement in the respective PROMIS domain T-score (Note: A higher PROMIS domain T-score represents more of the concept being measured. For the Ability to Participate in Social Roles and Activities domain an increase in T-score
Time frame: Baseline to Weeks 14, 30, and 52
To assess the efficacy of therapy in inducing a meaningful clinical improvement in pain interference through Week 52 through a reduction in PROMIS - Pain Interference - Short Form Scores.
Meaningful clinical improvement in each individual PROMIS domain at Weeks 14, 30, and 52
Time frame: Baseline to Weeks 14, 30, and 52
To assess the efficacy of therapy in inducing a meaningful clinical improvement in fatigue through Week 52 through a reduction in PROMIS - Fatigue - Short Form Scores.
Meaningful clinical improvement in each individual PROMIS domain at Weeks 14, 30, and 52
Time frame: Baseline to Weeks 14, 30, and 52
To assess the efficacy of therapy in inducing a meaningful clinical improvement in anxiety through Week 52 through a reduction in PROMIS - Emotional Distress - Anxiety - Short Form Scores.
Meaningful clinical improvement in each individual PROMIS domain at Weeks 14, 30, and 52
Time frame: Baseline to Weeks 14, 30, and 52
To assess the efficacy of therapy in inducing a meaningful clinical improvement in depression through Week 52 through a reduction in PROMIS Emotional Distress - Depression - Short Form.
Meaningful clinical improvement in each individual PROMIS domain at Weeks 14, 30, and 52
Time frame: Baseline to Weeks 14, 30, and 52
To assess the efficacy of therapy in inducing a meaningful clinical improvement in sleep disturbance through Week 52 through a reduction in PROMIS - Sleep Disturbance - Short Form.
Meaningful clinical improvement in each individual PROMIS domain at Weeks 14, 30, and 52
Time frame: Baseline to Weeks 14, 30, and 52
To assess the efficacy of therapy in inducing a meaningful clinical improvement in physical function through Week 52 through a reduction in PROMIS - Physical Function - Short Form.
Meaningful clinical improvement in each individual PROMIS domain at Weeks 14, 30, and 52
Time frame: Baseline to Weeks 14, 30, and 52
To assess the efficacy of therapy in inducing a meaningful clinical improvement in ability to participate in social roles and activities through Week 52 through a reduction in PROMIS - Ability to Participate in Social Roles and Activities - Short Form.
Meaningful clinical improvement in each individual PROMIS domain at Weeks 14, 30, and 52
Time frame: Baseline to Weeks 14, 30, and 52
To assess early change in patient-reported symptoms within the PRO-2 through Week 14.
Change in PRO-2 (liquid/very soft stool frequency + abdominal pain) from baseline to Week 14.
Time frame: Baseline to Week 14
To assess early change in patient-reported symptoms within the PROMIS - Pain Interference - Short Form through Week 14
Change in PROMIS Pain Interference-SF from baseline to Week 14.
Time frame: Baseline to Week 14
To assess early change in patient-reported symptoms within the PROMIS - Fatigue - Short Form through Week 14
Change in PROMIS Fatigue-SF scores from baseline to Week 14.
Time frame: Baseline to Week 14
To assess early change in patient-reported symptoms within the PROMIS - Anxiety - Short Form through Week 14
Change in PROMIS Anxiety-SF-scores from baseline to Weeks 2, 6, and 14.
Time frame: Baseline to Weeks 2, 6 and 14
To assess early change in patient-reported symptoms within the PROMIS - Depression - Short Form through Week 14
Change in PROMIS Depression- SF-scores from baseline to Weeks 2, 6, and 14.
Time frame: Baseline to Weeks 2, 6 and 14
To assess early change in patient-reported symptoms within the PROMIS - Sleep Disturbance - Short Form through Week 14
Change in PROMIS Sleep Disturbance- SF-scores from baseline to Weeks 2, 6, and 14.
Time frame: Baseline to Weeks 2, 6 and 14
To assess early change in patient-reported symptoms within the PROMIS - Physical Function - Short Form through Week 14
Change in PROMIS Physical Function- SF-scores from baseline to Weeks 2, 6, and 14.
Time frame: Baseline to Weeks 2, 6 and 14
To assess early change in patient-reported symptoms within the PROMIS - Ability to Participate in Social Roles and Activities - Short Form through Week 14
Change in PROMIS Ability to Participate in Social Roles and Activities- SF-scores from baseline to Weeks 2, 6, and 14.
Time frame: Baseline to Weeks 2, 6 and 14
To evaluate the association between the PRO-2 and each PROMIS domain
Correlation between PRO-2 scores and each individual PROMIS domain T-score • Correlation between change in PRO-2 scores and change in each individual PROMIS domain T-score
Time frame: Baseline to Weeks 14, 30, and 52
To assess the efficacy of therapy in resolving patient-reported symptoms by obtaining PRO-2 clinical remission, defined as a stool frequency score ≤ 3 and abdominal pain score ≤ 1 using unweighted subscores through week 52.
PRO-2 improvement (defined as a stool frequency score defined as a stool frequency score ≤ 3 and abdominal pain score ≤ 1 using unweighted subscores and no worsening of stool frequency and/or abdominal pain scores from baseline )
Time frame: Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52
To assess the efficacy of therapy in resolving patient-reported symptoms by obtaining PRO-2 clinical response, defined as a decrease in the weighted PRO-2 of ≥ 50% from baseline through week 52.
PRO-2 enhanced clinical response defined as a decrease in the weighted PRO-2 of ≥ 50% from baseline through week 52
Time frame: Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52
To assess the efficacy of therapy in resolving fecal urgency defined by a change in UNRS scores from baseline through week 52.
SIBDQ remission (defined as an SIBDQ score ≥ 60) at Weeks 2, 6, 14, 22, 30, 38, 46, and 52
Time frame: Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52
To assess the efficacy of therapy in resolving patient-reported symptoms and improving health related QOL as shown by SIBDQ improvement, defined as ≥ 9-point increase in the SIBDQ from baseline through week 52.
PRO-2 clinical response (defined as a decrease in the weighted PRO-2 of ≥ 50% from baseline) at Weeks 2, 6, 14, 22, 30, 38, 46, and 52
Time frame: Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52
To assess the efficacy of therapy in resolving patient-reported symptoms and improving health related QOL as shown by obtaining SIBDQ remission, defined as an SIBDQ score ≥ 60 through week 52.
PRO-2 clinical remission (defined as a stool frequency score ≤ 3 and abdominal pain score ≤ 1 using unweighted subscores) at Weeks 2, 6, 14, 22, 30, 38, 46, and 52
Time frame: Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52
To assess the durability of symptom improvement
PRO-2 clinical remission at Week 52 among participants who had PRO-2 clinical remission at Week 14
Time frame: Baseline to Week 14
To assess the efficacy of therapy in resolving patient-reported symptoms by obtaining PRO-2 clinical response through week 52.
PRO-2 clinical response defined as ≥ 30% decrease from baseline in unweighted stool frequency score or a ≥ 30% decrease from baseline in unweighted abdominal pain scores, with neither increasing from baseline
Time frame: Baseline to Weeks 2, 6, 14, 22, 30, 38, 46, and 52
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.
Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 33 months is below that.
Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alimentiv Inc.